Dr. Morgans is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-2698Fax+1 617-632-2165- Is this information wrong?
Education & Training
- Vanderbilt UniversityMPH, 2013 - 2015
- Vanderbilt University School of MedicineMPH, Epidemiology, 2013 - 2015
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2009
- Perelman School of Medicine at the University of PennsylvaniaClass of 2006
- Ursinus CollegeBS, Biology and Spanish, Summa Cum Laude, 2002
Certifications & Licensure
- MA State Medical License 2009 - 2026
- RI State Medical License 2022 - 2024
- IL State Medical License 2017 - 2023
- TN State Medical License 2012 - 2018
- PA State Medical License 2006 - 2009
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Goldberger Scholarship Vanderbilt University School of Medicine, 2013
- Honors in Biology Ursinus College, 2002
- Valedictorian Ursinus College, 2002
- Join now to see all
Clinical Trials
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01
- Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Start of enrollment: 2017 Mar 31
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Start of enrollment: 2021 Mar 01
Publications & Presentations
PubMed
- Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.Sentana-Lledo, D., Morgans, A.> ;Current Oncology Reports. 2024 Mar 1
- Plant-based diet associated with better quality of life in prostate cancer survivors.Loeb, S., Hua, Q., Bauer, S., Kenfield, S., Chan, J., Van Blarigan, E., Shreves, A., Mucci, L., Morgans, A.> ;Cancer. 2024 Feb 13
- Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer.Hong, A., Dufour, R., Marden, J., Kirson, N., Gatoulis, S., Kongara, S., Gandhi, R., Preston, M., Morgans, A.> ;European Urology Open Science. 2024 Feb 1
- Join now to see all
Journal Articles
- Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerPezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS..., Ann Oncol, 1/1/2017
- Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunctionKanz BA, Pollack MH, Johnpulle RA, Puzanov I, Horn L, Morgans AK, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB, Journal for ImmunoTherapy of Cancer, 1/1/2016
- Optimal management of muscle-invasive bladder cancer - a reviewScarpato KR, Morgans AK, Moses KA, Res Rep Urol, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Patient Expectations from Treatment of Incurable Metastatic Prostate Cancer.Morgans AK, Du L, Ahmed IA, Penson DF, Society of Medical Decision Making Annual Meeting, 1/1/2016
- Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of AGS15E (ASG-15ME) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC).D.P. Petrylak, E.I. Heath, G. Sonpavde, S. George, A. Morgans, B. Eigl, J. Picus, S. Cheng, S. Hotte, E. Gartner, M. Vincent, R. Chu, B. Anand, K. Morrison, L. Jackson..., American Society of Clinical Oncology Annual Meeting, 1/1/2016
- Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, Jarrard DF, Liu G, Morgans AK, Wong YN, Sweeney C, American Society of Clinical Oncology Annual Meeting, 1/1/2016
- Join now to see all
Lectures
- Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US c...2019 ASCO Annual Meeting - 6/1/2019
- Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Optimizing Patient-Centered Care and Follow-up in Prostate Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Authored Content
- Decision Analysis Defining Optimal Management of Clinical Stage 1 High-Risk Nonseminomatous Germ Cell Testicular Cancer with Lymphovascular InvasionMay 2018
Press Mentions
- Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley RossJanuary 22nd, 2023
- Advanced Prostate Cancer Practice Informing Data Presented at ASCO 2022 - Neeraj AgarwalJanuary 5th, 2023
- PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal PraDecember 5th, 2022
- Join now to see all
Grant Support
- Physician Research Training AwardDepartment of Defense2016–2020
- Durden Foundation Creativity AwardProstate Cancer Foundation2016–2018
Professional Memberships
- Member
- Member
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: